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Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of 
malignant plasma cells within the bone marrow. Bone marrow mesenchymal stromal 
cells (BMMSCs) represent a crucial component of MM microenvironment support-
ing its progression and proliferation. Alterations in BMMSC of MM (MM-BMMSC) 
have become an important research focus. In this study, we analyzed MM-BMMSC 
and their modification through interaction with plasma cells in 128 MM patients. 
MM-BMMSC displayed a senescence-like state that was accompanied by an increase 
in senescence-associated β-galactosidase activity, a reduced number of colony-forming 
units, an accumulation of cells in S phase of the cell cycle, and the overexpression 
of microRNAs (miR-16, miR-223, miR-485-5p, and miR-519d) and p21. MM-BMMSC 
showed a reduced expression of mitochondrial stress response protein SIRT3 and an 
increased mitochondrial DNA mass that led to a higher amount of reactive oxygen 
species compared to healthy donor BMMSC. The interaction between MM cells and 
MM-BMMSC is a complex mechanism that relies on multiple interacting signaling 
pathways. Observed aberrations in MM-BMMSC should be confirmed in an in vivo 
model in order to clarify the importance for the pathogenesis of MM. Eventually, the 
result of MM therapy could be improved by understanding the interaction between 
MM cells and MM-BMSCs.
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1. Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of 
malignant plasma cells within the bone marrow (BM) [1]. Contact between MM cells and 
their microenvironment plays a crucial role in MM survival and proliferation and is able 
to promote tumor progression and drug resistance. Bone marrow mesenchymal stromal 
cells (BMMSCs) represent a central component of MM microenvironment supporting its 
progression and proliferation [2–4]. Alterations in BMSC from MM patients (MM-BMMSC) 
have become an important research focus. Several studies and our previous data have sug-
gested the genesis of constitutive abnormalities within the BMMSC population through 
direct and indirect interactions with MM cells [5–8]. The development of a senescence-like 
state in BMMSC and thereby a modulated secretory profile, worsened osteogenic differen-
tiation potential and inhibition of the T-cell proliferation, was reported [6, 8, 9]. Senescent 
BMMSCs display an increased senescence-associated β-galactosidase activity (SAβGalA) 
and irregular cell morphology. Usually, the cell cycle of senescent cells is arrested at the G1/S-transition point in combination with the overexpression of different cell cycle inhibitors 
as p21 and p16. In spite of the aberrant growth characteristics, senescent cells remain meta-
bolically active, and therefore, the secretion of pro-inflammatory mediators could promote 
tumorigenesis in neighboring premalignant cells [10–12]. The secretion of pro-inflammatory 
mediators by senescent BMMSC could therefore promote tumorigenesis in neighboring pre-
malignant cells [13].
Two imprinted clusters in the human genome might contribute to the generation of senescence 
and the induction of cellular changes in MM-BMMSC [14–17]. The DLK1-DIO3 imprinted 
domain is located on chromosome 14q32.2, and cluster C19MC is located on chromosome 
19q13. The DLK1-DIO3 expresses the non-coding transcripts MEG3, anti-RTL1, 53 microR-
NAs (miRNA), and 2 snoRNA clusters on the maternal chromosome. The paternal chromo-
some is responsible for the transcription of the protein-coding genes DLK1, RTL1, and DIO3 
[18, 19]. Allelic expression of these genes is controlled through methylation of a regulatory 
region (IG-DMR) located upstream of the cluster [20]. The C19MC codes for 59 miRNAs are 
processed into one primary transcript from the paternal chromosome. Its expression strongly 
correlates with the epigenetic modulation of a CpG site located upstream [21].
In addition, there are evidence that the presence of cancer-associated fibroblasts (CAFs), char-
acterized by high α-SMA, FAP, and FSP-1 expression, in the BM samples of MM patients, 
contributes to altered, tumor favorable, cell-cell interactions and cytokine secretions [22–24].
BMMSC represents an essential part for assistance of MM partly by the secretion of tumor 
supportive cytokines as interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) 
[2]. Both of them play a major role in the aberration of multiple signaling pathways such as 
PI3K, JAK/STAT3, Raf, and NF-κB [25]. In addition, MM cells produce inflammatory mol-
ecules, such as TGFβ and TNFα, which lead to NF-κB activation tumor-promoting effects. The 
activation of the NF-κB pathway in both MM cells and BMMSC results in the downstream 
upregulation of adhesion molecules and a consequent increase in cell-cell interactions [26, 27]. 
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It is known that the increased activation of NF-κB together with the overexpression of adhe-
sion molecules can induce a therapy resistance [4, 26, 28, 29]. It can increase the secretion of 
tumor supportive soluble factors by BMMSC and may possibly lead to the generation of cell 
adhesion-mediated drug resistance [30–32].
Furthermore, additional interaction pathway, such as Notch signaling, is a factor between 
BMMSC and myeloma cells [33]. For example, it has been shown that malignant plasma cells 
overexpress the Notch ligand Jagged-2. An inhibition of Notch interaction induces myeloma 
cell apoptosis [34]. Notch signaling is important not only for the interaction of the myeloma 
cell with its surrounding cells but also for intercellular signaling between the malignant 
plasma cells. Downstream leads the Notch receptor-ligand interaction to an increased release 
of angiogenic and tumor-stimulating factors, such as VEGF, IL-6, and IGF-1 [35]. In addition, 
direct interaction between adhesion molecules (e.g., VCAM-1-VLA-4 interactions) and cell 
surface receptors such as Notch mediates therapy resistance and disease progression [36]. 
Furthermore, the formation of exosomes by BMSC, which actively transports modulatory 
substances, such as chemokines and miRNAs to the malignant MM cell, promotes survival 
and growth of MM cells. However, further investigations are needed to identify the exact 
mechanisms of exosome-mediated tumor promotion [37, 38].
It is known that cancer cells undergo dramatic alteration of metabolic pathways. Cancer cell 
survival and proliferation depend on metabolic processes, like glucose-uptake via altered 
glycolysis, also known as the Warburg effect. Sirtuins (SIRTs) are a family of deacylases 
and ADP-ribosyltransferases with clear links to regulation of cancer metabolism. Through 
their unique ability to integrate cellular stress and nutrient status in coordination with 
metabolic outputs, SIRTs are well poised to play pivotal roles in tumor progression and 
survival [39]. SIRT3 is the main mitochondrial deacetylase, which controls the activity of 
many metabolic enzymes in the mitochondria. SIRT3 deacetylates mitochondrial proteins 
that act in mitochondrial metabolism, including the oxidation of fatty acids, glutamine 
metabolism, and the production of mitochondrial reactive oxygen species (ROS) [40]. It 
was found that the increased level of cellular ROS observed with the loss of SIRT3 leads to 
a change in the cellular metabolism with respect to glycolysis. It is possible that the SIRT3 
deficiency leads to a cancer resolution, coordinating the metabolic shift in the Warburg 
phenotype [41].
Despite some knowledge of the constitutive changes in the BMMSC of MM patients, the 
molecular mechanisms and pathways that induce abnormalities are largely unknown.
2. Patients and methods
2.1. Patients and donor characteristics
BM samples from 116 MM patients were studied: 69 patients with MM at the time of diagnosis 
and 47 at relapse. All patients had indications for treatment. The main clinical characteristics 
Molecular Aberrations in Bone Marrow Stromal Cells in Multiple Myeloma
http://dx.doi.org/10.5772/intechopen.77179
121
of patients are shown in Table 1. Twelve bone marrow aspirates were received from healthy 
donors (HDs) as control. Written informed consent was obtained from all patients and donors in 
accordance with the Declaration of Helsinki and the ethical guidelines of the Charité University 
School of Medicine, which approved this study (Votum No.: EA4/131/13).
2.2. Isolation of BMSC and CD138+ plasma cells
BMMSCs from patients and donors (HD-BMMSC) were isolated using adhesion method and 
cultivated as previously described [42–44]. The colony-forming unit fibroblast (CFU-F) assay 
was used to study the self-renewal capacity of BMMSC. The staining was carried out with the 
Hemacolor Rapid Staining Kit from Merck according to the manufacturer’s instructions. The 
evaluation was done by counting blue colonies.
Non-hematopoietic cell characteristics were identified by flow cytometry by the absence of 
CD105-FITC, CD90-FITC, CD45-PE, and CD34-PE (Miltenyi). Data were acquired and ana-
lyzed with a FACS Calibur Flow Cytometer (BD Biosciences). Control CD138+ plasma cells 
were isolated from HD mononuclear cells using magnetic-activated cell sorting (MACS) with 
a CD138 antibody (Miltenyi) as recommended by the manufacturer’s protocol and seeded in 
culture flask with RPMI media with 20% of fetal calf serum and antibiotic/antimycotic.
Characteristics All patients
(n = 116)
Patients at 
diagnosis
(n = 69)
Patients at 
relapse
(n = 47)
Donors
(n = 16)
Age, median (range) 63 (33–87) 64 (33–87) 62 (57–84) 69 (38–81)
Gender (M/F, %) 66/34 67/33 66/34 62/38
Ig expression (%)
IgG 58 60 53
IgA 13 14 13
IgD 1 0 2
Light chain 27 25 32
Non-secretary 1 1 0
Stage on Durie-Salmon (%)
I A 10 13 7
I B 6 8 2
II A 8 6 11
II B 5 3 7
III A 55 54 57
III B 16 16 16
Bone marrow infiltration % median 
(range):
50 (10–100) 60 (10–100) 40 (5–90)
Table 1. Patients and donor characteristics.
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2.3. Co-culture and transwell culture experiments
KMS12-PE cells received from DSMZ (ACC606) were cultured in enriched RPMI media. For co-
cultures, MM-BMMSCs were seeded in a six-well plate and incubated for 4 h. Then, KMS12-PE 
myeloma cells were added followed by incubation for 72 h. After incubation, KMS12-PE cells 
were removed. The absence of CD138+ cells was confirmed using microscopy and checked 
with FACS analysis. MM-BMMSCs were washed twice with PBS and applied for future analy-
sis. Co-cultured KMS12-PE myeloma cells were suspended in TRIzol for future analysis.
For transwell cultures (0.4 μM pore size, Corning), 2 × 104 MM-BMMSCs were seeded in the 
lower chamber of a 12-well plate and incubated for 4 h. Then, 2 × 104 KMS12-PE myeloma 
cells were added to the upper chamber. Incubation was performed for 72 h. Cultures without 
KMS12-PE cells served as negative control for transwell cultures and co-cultures.
2.4. Detection of SAβGalA and cell cycle analysis
SAβGalA was measured using the median fluorescence intensity (MFI) as previously reported 
[45]. Co-cultures of HD-BMMSC and HS-5 stromal cells (CRL-11882) were used as controls. 
In addition, β-galactosidase activity was analyzed using the “Senescence Cells Histochemical 
Staining Kit” (Sigma-Aldrich) as recommended by the manufacturer. Cell cycle analysis was 
performed using the “Cell Cycle Assay Kit” (Abcam) as recommended in the prescription. 
Data were studied using a logarithmic scale.
2.5. Quantitative real-time PCR (qPCR)
Total RNA was extracted using TRIzol as described previously [46]. RNA was treated with 
DNase (Ambion) and poly(A)-polymerase (NEB) according to the manufacturer’s instructions. 
About 800 ng of RNA was used for cDNA synthesis with a Transcriptor First Strand cDNA 
Synthesis Kit (Roche) and 2.5 μl of poly(T)VN adaptor primer (10 pmol) in a 20 μl reaction.
qPCR was performed with the FastStart Universal SYBR Green Master Mix (Roche). Primers 
were designed for each mRNA target using Primer3, OligoCalc, and OligoIDT. MiRNA detec-
tion was conducted using a specific miRNA primer and a universal reverse primer comple-
mentary to the adaptor sequence [47]. GAP-DH (for mRNA) and 5.8S rRNA (for miRNA) 
were chosen as housekeeping genes. QPCR was carried out with the Rotor Gene 6000 Real-
Time PCR cycler. Cycling condition comprised 10 min at 95°C, 45 cycles of 15 s at 95°C and 
60 s at 59°C, followed by a melting curve analysis from 60 to 98°C, rising by 1°/s. Efficiencies 
of qPCR were determined using linear regression analysis [48, 49] using LinRegPCR software, 
and relative quantifications were estimated with the Pfaffl method [50]. Received data were 
analyzed with the Rotor Gene 6000 software.
2.6. Quantitative methylation-specific PCR (qMSP)
DNA isolation was performed using Puregene reagents (Qiagen) according to the manu-
facturer’s instructions. Genomic DNA was subjected to bisulfite treatment with the EpiTect 
Fast Bisulfite Conversion Kit (Qiagen) as recommended in the manual. Primers were used as 
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described by Murphy et al. [51] for DLK1-DIO3 and Fornari et al. [52] for C19MC. Reactions 
were performed with 30 ng treated DNA using SYBR Green Master Mix (Roche). Quantification 
was carried out using a standard curve generated using a dilution series of fully methylated 
with unmethylated DNA (Applied Biosystems). Each sample was analyzed in duplicates, and 
Ct values above 32 were excluded.
2.7. Copy number (CN) variation analysis
Three genomic regions located along each of the clusters were chosen for CN estimations of 
DLK1-DIO3 and C19MC. Assay qBiomarker Copy Number (Qiagen) was used. Genomic DNA 
from the stromal cell line HS-5 (CRL-11882) was applied as a calibrator. Analysis was performed 
with 5 μl of SYBR Green Master Mix, 0.5 μl of respective copy number assay, and 2 ng of genomic 
DNA in a total volume of 10 μl. Relative quantification was achieved by the ΔΔC
t
 method.
2.8. Transfection of SIRT3 siRNA
The transient knockdown of SIRT3 was performed in HD-BMMSC using siRNA (Qiagen). 
The transfections were carried out in 6-well and 24-well plates. For a 24-well plate, 33 nM 
siRNA was mixed with 6 μl HiPerFect Transfection Reagent in 100 μl serum-free medium and 
incubated for 10 min at room temperature. The cells were incubated for 48 h and then used for 
future analyses. For a six-well plate, the cell number was constant, and the reagent volumes 
were scaled up accordingly.
2.9. Determination of mitochondrial membrane potential and reactive oxygen 
species
Investigation of ROS amount was carried out using the DCFDA—cellular Reactive Oxygen 
Species Detection Assay Kit (Abcam) as recommended in the instruction. Analysis was con-
ducted using the median fluorescence intensity.
Analysis of mitochondrial membrane potential (ΔΨm) was performed with the Mitochondria 
Staining Kit (Sigma) using JC-1 dye. Results were analyzed using the ratio of JC-1 aggregates 
(median value of FL2 channel) to JC-1 monomers (median value of FL21 channel).
2.10. Indirect enzyme-linked immunosorbent assay (ELISA)
Proteins from complete cell lysates of BMMSC were detected with a Coomassie (Bradford) 
Protein Assay Kit (Pierce) and were adjusted with BupH Coating Buffer (Pierce). Analyses 
were performed according to the commercially available indirect ELISA protocol from Abcam. 
Detection was performed with 1-Step pNpp-Substrate (Pierce). Absorption was measured at 
405 nm. All measurements were performed with three technical replicates. A dilution series of 
complete cell lysates of the HS-5 cell line was used for standard curve generation.
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 software (La Jolla, CA, USA). 
The data shown represent the mean ± standard error of the mean (SEM). Comparisons of 
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HD-BMMSC with MM-BMMSC were performed using the Mann-Whitney U test. The 
Wilcoxon signed-rank test was used for the analysis of co-cultures. Results were considered 
statistically significant when p ≤ 0.05.
3. Results
3.1. MM-BMMSCs are characterized by high senescence state and cell cycle abnormalities
Analysis of β-galactosidase activity revealed a significantly higher SAβGalA in MM-BMSC 
when compared with HD-BMDSC (Figure 1A). Since no significant differences in senescent 
cells between passages 1 and 4 were observed in both MM-BMMSC and HD-BMMSC, we can 
exclude the effect of cultivation on SAβGalA. These results were confirmed by a histological 
β-galactosidase staining of HD-BMMSC and MM-BMMSC in passage 4.
Figure 1. MM-BMMSC exhibits a higher senescence state and a lower self-renewal capacity than HD-BMMSC. P values: 
* <0.05; ** <0.01; *** <0.001; and **** <0.0001. All data were analyzed using the Mann-Whitney U test and unpaired t-test (ELISA 
analysis). (A) Flow cytometric analysis of SAβGalA. ND-MM-BMMSCs and R-MM-BMMSCs displayed higher activity of 
SAβGalA in passages 1 and 4 of cell cultures compared to HD-BMMSCs. (B) The colony-forming unit fibroblast (CFU-F) 
assay was used to study the self-renewal capacity of BMMSC. MM-BMMSC showed a lower self-renewal capacity compared 
to HD-BMMSC. (C) Cell cycle analysis showed a higher amount of cell in S phase and amount in G1/G0 phase in MM-BMMSC compared to HD-BMMSC. (D) QPCR analysis displayed decreased cyclin E1, increased cyclin D1 and p21 expression in 
MM-BMMSC compared to HD-BMMSC. (E) Measurement of the protein level in HD-BMMSC and MM-BMMSC. Cyclin 
E1 was significantly decreased in MM-BMMSC compared to HD-BMMSC, whereas cyclin D1 and p21 were increased. The 
protein amount of p16 was slightly reduced in MM-BMMSC compared to HD-BMMSCs. ND-MM-BMMSCs, new diagnosed 
MM patients; R-MM-BMMSCs, MM patients in relapse; HD-BMMSCs, healthy donor control.
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The colony-forming unit fibroblast (CFU-F) assay was used to study the self-renewal capacity 
of BMMSC. MM-BMMSC showed a lower self-renewal capacity compared to HD-BMMSC 
(Figure 1B). Similar to the senescence study, MM-BMMSC obtained from relapsed patients 
showed a significantly lower self-renewal capacity than MM-BMMSC, which forms newly 
diagnosed patients.
MM-BMMSCs are characterized by a lower expression of cyclin E1 and an overexpression of 
cyclin D1 when compared with HD-BMMSC (Figure 1D). In addition, the cell cycle inhibitor 
p21 was upregulated in MM-BMMSC compared to HD-BMMSC (p < 0.05). No changes were 
observed in the mRNA level of p16. Changes in the mRNA levels were also confirmed using 
protein analysis (p < 0.03; Figure 1E). Cyclin E1 was decreased in MM-BMMSC compared to 
HD-BMMSC (p = 0.0416). Cyclin D1 and p21 protein levels were 1.5- to 1.8-fold increased. 
Protein measurement also showed a slightly reduced level of p16 in MM-BMMSCs, but this 
change was below 1.5-fold. These results correlated with a higher number of cells in S phase 
and a reduced number of cells in G1/G0 phase compared to HD-BMMSCs (p < 0.008; Figure 1C).
3.2. Co-culturing of KMS12-PE cell line represses the senescence entry of 
MM-BMMSCs
Co-cultures of the KMS12-PE cell line with MM-BMMSC and HD-BMMSC were carried 
out to analyze whether MM cells can exert an influence on the senescence characteristics of 
BMMSC. Experiments were performed with MM-BMMSC (n = 20) and HD-BMMSC (n = 3). 
After co-culturing BMSC with MM cells, an inhibition of senescence entry in MM-BMMSC 
was observed. SAβGalA activity was significantly reduced (Figure 2A). A similar effect was 
detected using transwell cultures to prevent cell-cell contact between MM-BMMSC and 
KMS12-PE cells (p < 0.0313; Figure 2A). No effect on the activity of SA-βGal was observed in 
HD-BMMSC and the HS-5 cell line co-cultured with KMS12-PE myeloma cells. Interestingly, 
CD138+ plasma cells from healthy donors induced a downregulation of SAβGalA activity in 
MM-BMMSC. However, this influence was three- to sixfold lower than that of observed in 
co-cultures with KMS12-PE cells. These results indicate that MM cells have a higher and more 
specificity proliferation stimulation effect on BMMSC compared to CD138+ plasma cells.
Also, mRNA expression of co-cultured and transwell cultured MM-BMMSCs was measured 
(Figure 2B). No changes were found for cyclin D1 and p16, whereas cyclin E1 was upregu-
lated in both co-cultured and transwell cultured MM-BMMSC (p < 0.05). BMSC interaction 
with MM cells has induced an upregulation of p21. This effect was lower in transwell cultured 
MM-BMMSC compared to co-cultured MM-BMMSC (p < 0.008).
However, some contrary results were detected at the protein level. We have found a reduction 
in p21 in co-cultured MM-BMMSC (Figure 2C). In addition, cyclin D1 protein expression was 
1.8-fold reduced upon co-cultivation with KMS12-PE myeloma cells, whereas no change was 
seen on mRNA level (p = 0.0033). The mRNA and protein analysis of cyclin E1 and p16 were 
concordant.
Next, we analyzed cell cycle distribution of co-cultured and transwell cultured MM-BMMSC 
(Figure 2D). Both cell culture systems led to a slight reduction in cells in S phase compared to 
MM-BMMSC cultured alone (p = 0.008) and an increase in the percentage of cells in G1/G0 phase 
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when compared with mono-cultured MM-BMMSC (p = 0.008). Transwell cultured MM-BMMSCs 
showed the same tendency, but significant changes were not detectable.
3.3. Deregulation of microRNA expression in MM-BMSC
We chose six microRNAs, which were previously reported to be deregulated in MM cells 
and to play a possible role in the generation of senescence or cell cycle arrest (miR-16, miR-
485-5p, miR-519d, miR-221, miR-126, and miR-223). Analysis revealed an overexpression of 
miR-16, miR-223, miR-485-5p, and miR-519d (all with p < 0.025) in MM-BMMSCs compared to 
HD-BMMSCs. No expression differences were detected for miR-221 and miR-126 (Figure 3A).
We revealed the overexpression of miR-485-5p and miR-519d in MM-BMMSCs. These 
microRNAs are located on two imprinted clusters on chromosomes 14 (DLK1-DIO3) and 19 
(C19MC), respectively, and are reported to play a role in senescence generation [21, 31, 32]. 
Figure 2. KMS12-PE myeloma cells reduce SAβGalA and modify cell cycle characteristics of MM-BMMSC. P values: 
* <0.05; ** <0.01; *** <0.001; and **** <0.0001. All data were analyzed using the Wilcoxon signed-rank test and paired t-test 
(ELISA analysis). HS-5 (CRL-11882)—BMSC line. (A) KMS12-PE myeloma cells reduce SAβGalA in MM-BMMSC upon 
co-cultivation and cultivation in transwell. The MFI in MM-BMMSC was significantly reduced in both culture systems. 
No changes were observed for co-cultured HD-BMMSC and HS-5 cells indicating specificity of the measured effect for 
MM-BMMSC. (B) Cell interaction with KMS12-PE myeloma cells induced increased cyclin E1 and p21 expression in 
MM-BMMSC compared to MM-BMMSC cultured alone. (C) Protein expression analysis of co-cultured MM-BMMSC 
(n = 3) compared to mono-cultured MM-BMMSC. Cyclin E1 was increased, whereas cyclin D1 and p21 were reduced in 
co-cultured cells compared to mono-cultures. No change was seen for p16. (D) Cell interaction with KMS12-PE myeloma 
cells induced an increase in cells in G1/G0 phase and reduced the amount of cells in S phase in co-cultured and transwell 
cultured MM-BMMSCs (n = 8) compared to the same MM-BMMSC cultured alone.
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Figure 3. Overexpressed microRNAs in MM-BMMSC are associated with hypomethylation and CN accumulation 
of DLK1-DIO3 and C19MC. P values: * <0.05; ** <0.01; *** <0.001; and **** <0.0001. All data were analyzed using the 
Mann-Whitney U test. (A) ND-MM-BMMSC and R-MM-BMMSC showed high overexpression of miR-16, miR-485-5p, 
miR-519d, and miR-223 compared to HD-BMMSCs. (B) The regulatory regions of DLK1-DIO3 and C19MC were 
hypomethylated in ND-MM-BMMSC and R-MM-BMMSC compared to HD-BMMSC. (C) CN analysis of C19MC 
displayed CN accumulation in all three regions in MM-BMMSC compared to HD-BMMSC. (D) CN analysis of DLK1-
DIO3 displayed CN accumulation in all three measured positions in MM-BMMSCs compared to HD-BMMSC.
Given that the expression of both clusters is controlled by methylation of their regulatory 
regions, we analyzed their methylation status using qMSP (Figure 3B). Hypomethylation of 
both clusters in MM-BMMSCs compared to HD-BMMSCs was observed. For DLK1-DIO3, 
MM-BMMSC exhibited an approximate fivefold lower methylation level of the IG-DMR. The 
C19MC exhibited a 2.5-fold lower methylation level in MM-BMSC compared to HD-BMMSC 
(p = 0.0062). CN analysis of both clusters displayed CN accumulation in all three regions in 
MM-BMMSC (n = 38) compared to HD-BMMSC (n = 8; Figure 3C and D).
3.4. Co-culturing of MM-BMSC with the KMS12-PE cell line induces the changes of 
microRNA expression in both cell types
The expression of four miRNA (miR-16, miR-223, miR-485-5p, and miR-519d) after co-culturing 
and transwell cultured MM-BMMSC was measured using qPCR (Figure 4A). MiR-223 was down-
regulated in co-cultured MM-BMMSC (p < 0.007), whereas no effect was detected in transwell 
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cultured MM-BMMSC. In contrast, downregulation of miR-485-5p was detected in both cell 
culture systems (p < 0.03). Interestingly, cell-cell interaction also altered miRNA expression of 
KMS12-PE myeloma cells. We found upregulation of miR-221 and significantly downregulation 
of miR-223 and miR-519d (p < 0.02; Figure 4B). Expression of miR-485-5p was not detectable in 
KMS12-PE myeloma cells.
3.5. KMS12-PE cells modulate the gene expression of MM-BMMSC
To explore the influence of KMS12-PE cells on gene expression of adhesion molecules, 
qPCR analysis of MM-BMMSC, co-cultured for 72 h with KMS12-PE cells in passage 4, was 
performed (n = 25). In mono-cultured BMSC, an upregulation of VCAM-1 (p = 0.33), ICAM-1 
(p = 0.33), and IKK-α (p = 0.05) was demonstrated. Furthermore, the expression profile of 
miRNAs, targeting the analyzed genes or correlating with senescence, was studied (miR-
16, miR-221, miR-126, miR-223, miR-485-5p, and miR-519d). MiR-16, miR-223, miR-485-5p, 
and miR-519d were significantly upregulated (p = 0.02; p = 0.004; p = 0.02; and p = 0.002, 
respectively), whereas miR-221 and miR-126 showed no considerable differences to BMSC 
obtained from healthy donors. After co-culturing of MM-BMSC with KMS12-PE cells, an 
enhanced expression of adhesion molecules was apparent. This includes the upregula-
tion of VCAM-1 (p = 0.0078), ICAM-1 (p = 0.2425), and NF-κB activator IKK-α (p = 0.0573), 
though the values for ICAM-1 and IKK-α were not significant. Hence, MM cells seem to 
further boost the aberrant expression of adhesion molecules in MM-BMMSCs. Regarding 
microRNAs, a significant downregulation of miR-223 and miR-485-5p (p < 0.009) was 
detected. In addition, miR-16 and miR-519d showed a trend toward downregulation, 
though the changes were not significant. No expression alterations to miR-221 or miR-126 
were detected (data not shown).
Figure 4. KMS12-PE myeloma cells downregulate miR-223 and miR-485-5p in MM-BMMSC. P values: * <0.05; ** <0.01; 
*** <0.001; and **** <0.0001. All data were analyzed using the Wilcoxon signed-rank test. (A) Co-cultured MM-BMMSC 
(n = 25) displayed reduced expression of miR-223 and miR-485-5p. Transwell-cultured (n = 10) MM-BMMSC showed no 
changes in miR-223 expression but also decreased miR-485-5p levels. Intensity of changes in miR-485-5p decreased when 
cell-cell contact was prevented by transwell cultivation. (B) Cell interaction with MM-BMMSC induced changes in the 
microRNA expression of KMS12-PE myeloma cells (n = 10). MiR-221 was upregulated, whereas miR-223 and miR-519d 
decreased in co-cultured KMS12-PE myeloma cells.
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3.6. Expression of metabolic regulators in MM-BMSC
We investigated whether metabolic changes in MM-BMMSC could be responsible for the early 
aging status of the cells. For this purpose, we analyzed the expression of the gene and protein 
of the metabolic molecules SIRT3 and UCP2 and the lactate transporter MCT1 and MCT4.
There were no significant differences in the gene expression of MCT1, MCT4, and UCP2 in 
MM-BMMSC compared to HD-BMMSC (data not shown). In contrast, a significant lower 
expression of SIRT3 was detected in MM-BMMSC (p < 0.001; Figure 5A). All data were 
reproduced at the protein level. In addition, it was investigated whether MM-BMMSCs 
have an increased mitochondrial mass in comparison with HD-BMMSC. For this purpose, 
mtDNA was quantified and was normalized to the content of nuDNA. It was shown that 
MM-BMMSCs show a significant increase in mitochondrial mass compared to HD-BMMSC 
(p = 0.0149; Figure 5B). These changes were not detected in MGUS-BMMSC (n = 4), suggesting 
an association with disease progression.
Figure 5. SIRT3 expression and mtDNA mass in MM-BMMSC. P values: * <0.05; ** <0.01; *** <0.001; and **** <0.0001. All 
data were analyzed using the Wilcoxon signed-rank test. (A) MM-BMSC displayed a twofold decrease in the expression 
of SIRT3 compared to HD-BMSC. MGUS-BMSC showed no changes. (B) MM-BMSC showed a twofold increase in 
mtDNA mass compared to HD-BMSC. (C) Co-cultured MM-BMSC displayed a fourfold increase in SRT3 mRNA level. 
No changes were seen in transwell cultures. (D) Co-cultivation KMS12-PE and MM-BMSC induced depolarization of 
ΔΨm. (E) Co-cultivation KMS12-PE and MM-BMSC reduced the amount of ROS in both cell systems.
Stromal Cells - Structure, Function, and Therapeutic Implications130
To explore the influence of MM cells on SIRT3 expression in BMSC, co-culturing for 72 h with 
KMS12-PE cells (n = 20) and transwell experiments (n = 10) was performed. Interestingly, we 
found a fourfold upregulation of SIRT3 expression in MM-BMMSC when co-cultured with 
KMS12-PE myeloma cells (Figure 5C). No changes were seen in transwell cultures.
Moreover, co-cultivation induced depolarization of ΔΨm leading to an approximately two-
fold JC1 monomers increasing in MM-BMSC and MM cells (Figure 5D). Co-cultivation of 
KMS12-PE and MM-BMSC reduced the amount of ROS in both cell systems (Figure 5E).
To further elucidate the involvement of SIRT3 in metabolic and senescence-like alterations 
of MM-BMMSCs, siRNA was used to transiently “knockdown” this gene in HD-BMMSC. 
Figure 6. Influence of SIRT3 on ROS in HD-BMMSC. P values: * <0.05; ** <0.01; *** <0.001; and **** <0.0001. (A) The 
knockdown of SIRT3 in HD-BMMSC caused an increase in the ROS content of all four siRNAs tested compared to 
the negative and transfection control. (B) Influence of SIRT3 on ΔΨm in HD-BMMSC. The “knockdown” of SIRT3 in 
HD-BMMSC caused a reduction in the FL-2/FL-1 ratio. For siRNAs 2 and 3, only the proportion of FL-1 negative cells was 
reduced (R-4), whereas siRNAs 4 and 5 also caused an increase in FL-2 negative cells (R-3). (C) Influence of SIRT3 on cell 
cycle in HD-BMMSC. The “knockdown” of SIRT3 in HD-BMMSCs led to an accumulation of cells in S phase of the cell 
cycle (siRNAs 4 and 5). siRNAs 2 and 3 produced effects of the same tendency, but these were very low (<5%). (D) Influence 
of SIRT3 on senescence-associated β-galactosidase activity HD-BMMSC. Transfection of HD-BMMSCs with siRNAs 4 and 
5 produced an increase in SAβGalA. In contrast, no significant effects were observed for siRNA 2 and siRNA.
Molecular Aberrations in Bone Marrow Stromal Cells in Multiple Myeloma
http://dx.doi.org/10.5772/intechopen.77179
131
Subsequently, the ROS amount, mitochondrial membrane potential, cell cycle, and SAβGalA of 
the cells were investigated. Two different HD-BMMSCs were used for these analyses, and from 
each study, 2–3 replicates were performed. The donors were 73 and 74 years old. Furthermore, 
four different siRNAs against SIRT3 were used. SIRT3 knockdown in HD-BMMSC induced 1.4- 
to 1.9-fold increase in ROS levels (p < 0.05; Figure 6A). This was associated with dissipation of 
ΔΨM between 1.4- and 1.8-fold depending on the siRNA that was used for transient knockdown 
of SIRT3 (p < 0.04; Figure 6B). Furthermore, the inhibition of SIRT3 mimicked cell cycle arrest 
in S phase previously reported in BMMSC of myeloma patients. The percentage of BMMSC 
in S phase increased upon SIRT3 knockdown between 6.7 and 9.6% (p < 0.039; Figure 6C). In 
addition, it was investigated whether the depletion of SIRT3 increases senescence-associated 
β-galactosidase activity. It was found that transfection of HD-BMMSC with SIRT3 siRNAs 4 and 
5 resulted in an approximately 1.5-fold increase in SAβGalA (p < 0.03). In contrast, HD-BMMSCs 
transfected with siRNA 2 did not show any changes. Similarly, transfections with siRNA 3 
caused only minimal changes in HD-BMMSCs (Figure 6D).
4. Discussion
MM-BMMSCs play a critical role in MM tumor growth and survival. Several studies suggest 
the existence of constitutive abnormalities in MM-BMMSC, and these lead to abnormal cell 
characteristics and increased tumor support [5, 6, 9, 23, 53, 54]. In this study, we explored the 
cellular and genetic aberrations of MM-BMMSCs in order to further identify the molecular 
mechanisms for these changes.
The enhanced and early senescence of BMMSC has been previously reported for different 
hematological disorders, including MM [9, 55]. Here, a significant higher senescence level 
of MM-BMMSC compared to HD-BMMSC was identified. When combined with our qPCR 
results that revealed an enrichment of cyclin D1 mRNA and the reduced expression of cyclin 
E1, an arrest of the cell cycle in G1 phase can be assumed. In contrast, André et al. related senes-
cence to an accumulation of MM-BMMSCs in S phase [9]. These contrasting results could be 
due to diverse patient samples as well as different cell isolation and culture treatment meth-
ods. However, early senescence indicates the impairment of MM-BMMSCs. With regard to 
the relapsed analysis group, therapy might lead to increased cellular stress for MM-BMMSCs 
resulting in higher senescence levels.
Distinct changes to gene expression profiles were also reported [24, 56–59]. In addition to the 
abovementioned changes in cyclin expression, an upregulation of the cell adhesion molecules 
VCAM-1 and ICAM-1, as well as the NF-κB member IKK-α, was found, consistent with pre-
vious studies [6, 9, 53]. Overexpression of the cell adhesion molecules and the NF-κB path-
way without MM-BMMSC in contact with MM cells suggests the generation of a constitutive 
myeloma favorable microenvironment.
In contrast to the above studies, data relating to microRNA expression in MM-BMMSCs are lim-
ited. Here, overexpression of miR-16, miR-223, miR-485-5p, and miR-519d was identified. These 
microRNAs possibly influence cell cycle regulation, cell differentiation, and cell migration. 
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Alterations to MM-BMMSCs could therefore result from the specific deregulation of microRNA 
expression and their corresponding downstream targets [15, 52, 60–66]. The relapsed analy-
sis group displayed a higher senescence level and a strongly increased microRNA expression 
(mean fold change > 100), supporting their possible function as cell cycle modifiers. Therapy 
seems to enforce senescence in MM-BMMSCs due to higher cellular stress and could lead to an 
even more altered cellular phenotype at relapse.
Overexpressed miR-485-5p and miR-519d are associated with two imprinted clusters on 
chromosomes 14 (DLK1-DIO3) and 19 (C19MC), respectively. Since both clusters exhibit a 
complex composition, including tumor-suppressive as well as tumor-promoting microR-
NAs, changes to their epigenetic regulation could account for important changes to the 
cellular characteristics of MM-BMMSCs [21, 66]. Here, analysis revealed hypomethylation 
and amplification of both clusters, possibly resulting in a higher transcriptional rate of 
cluster-associated genes. Several studies have reported the accumulation of genomic and 
global methylation changes due to in vitro cultivation of BMMSCs [67–72]. Indeed, minimal 
changes in the HD-BMMSC population, for example, hypo- and hypermethylation, as well 
as CN values between 2.2 and 2.8, were found. However, these alterations were less than 
those found in MM-BMMSCs, with distinct clustering of MM-BMMSC values below 20% 
methylation level and a mean value of more than 3.5 copies of the DLK1-DIO3 and C19MC 
genomic regions. The detected aberrations could be due to the existence of a CAF popula-
tion in the MM-BMMSCs because some data highlight the presence of DNA hypometh-
ylation and genetic instability in CAFs [24, 56, 73]. However, genetic instability in CAFs 
is controversial [74]. Hence, it cannot be excluded that CN variations of DLK1-DIO3 and 
C19MC result from hypomethylation or vice versa.
Moreover, the effect of MM cells on previously identified gene expression variations was 
investigated. In this context, a proliferation stimulating influence of KMS12-PE myeloma 
cells on MM-BMMSCs was apparent. Thus, KMS12-PE cells appear to repress MM-BMMSC 
senescence entry and increase the cell vitality. This modification could be associated with an 
increase in cyclin E1 mRNA levels.
Lastly, we investigated whether metabolic changes in MM-BMMSC could be responsible 
for the early aging status of the cells. For this purpose, we analyzed the expression of the 
gene and protein of the metabolic molecules SIRT3 and UCP2 and the lactate transporter 
MCT1 and MCT4. There were no significant differences in the gene expression of MCT1, 
MCT4, and UCP2 in MM-BMMSC compared to HD-BMMSC. In contrast, a significant 
lower expression of SIRT3 and a significant increase in mitochondrial mass compared were 
detected in MM-BMMSC. Interesting, no changes were detected in MGUS-BMMSC, sug-
gesting an association with disease progression.
Our results suggested that MM cells influence the mitochondrial function of MM-BMMSC. This 
interaction leads to decrease the ROS levels in both cell types and could support their survival 
and growth. Moreover, the sustained induction of mitochondrial stress response could be 
the reason for premature senescence in MM-BMMSC. Therefore, the result of MM therapy 
could be improved through the disabling of metabolic interactions between MM cells and 
MM-BMMSC.
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